About 50% of AML patients do not carry NPM1 mutations or recurrent fusion genes, and in this context, there is an urgent need to introduce novel molecular MRD techniques in order to monitor a broader range of AML patients. This evidence concerns the gene NPM1 and acute myeloid leukemia.